S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China

Innovus Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:INNVD)

Compare
Today's Range
N/A
50-Day Range
$3.00
$3.00
52-Week Range
N/A
Volume
4,300 shs
Average Volume
9,592 shs
Market Capitalization
$7.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

INNVD stock logo

About Innovus Pharmaceuticals Stock (OTCMKTS:INNVD)

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.


INNVD Stock News Headlines

Impel Pharmaceuticals Inc IMPL
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Telcon RF Pharmaceutical Inc.
Where Olema Pharmaceuticals Stands With Analysts
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Inovio Pharmaceuticals Inc. Q2 Loss decreases, beats estimates
Rafarma Pharmaceuticals Inc.
See More Headlines
Receive INNVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2019
Today
12/02/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:INNVD
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-8,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$23.99 million
Book Value
$0.05 per share

Miscellaneous

Free Float
N/A
Market Cap
$7.07 million
Optionable
Not Optionable
Beta
2.89
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Bassam B. Damaj (Age 51)
    Pres, CEO & Director
  • Mr. Ryan J. Selhorn CPA (Age 37)
    VP & CFO
  • Mr. Randy J. Berholtz (Age 58)
    Exec. VP of Corp. Devel., Gen. Counsel & Sec.
  • Mr. Christopher Stella
    VP of Operations
  • Mr. Robert C. Verfurth
    VP of Sales & Marketing














INNVD Stock Analysis - Frequently Asked Questions

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNVD) issued its quarterly earnings results on Monday, April, 1st. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.12. The firm had revenue of $4.75 million for the quarter, compared to analysts' expectations of $8.13 million. Innovus Pharmaceuticals had a negative trailing twelve-month return on equity of 682.54% and a negative net margin of 34.51%.

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:INNVD) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -